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Background: The presence of nerve damage plays a key role in the development and prognosis of chronic pain
states. Assessment of the presence and severity of a neuropathic pain component (NePC) is key in diagnosing
chronic pain patients. Low back pain (LBP) and neck and shoulder pain (NSP) are highly prevalent and clinically
important medical and societal problems in which a NePC is frequently present. The more severe the NePC, the
worse the course of the pain, its prognosis and the results of treatment. Reliable and standardised diagnosis of the
NePC remains difficult to achieve. Standardized and validated screening tools may help to reliably identify the NePC
in individual chronic pain patients. The aim of this study is to validate the Dutch language versions of the
PainDETECT Questionnaire (PDQ-Dlv) and the ‘Douleur Neuropathique 4 Questions’ (DN4-Dlv) for use in primary and
specialist medical care settings to screen for a NePC in patients with chronic pain due to (1) LBP, (2) NSP or (3)
known peripheral nerve damage (PND).
Methods/design: The study design is cross-sectional to assess the validity of the PDQ-Dlv and the DN4-Dlv with
2 weeks follow-up for test-retest reliability and 3 months follow-up for monitoring and prognosis. 438 patients with
chronic pain due to (1) LBP, (2) NSP or (3) PND. will be included in this study. Based on the IASP definition of
neuropathic pain, two physicians will independently assess whether the patient has a NEPC or not. This result will
be compared with the outcome of the PDQ-Dlv & DN4-Dlv, the grading system for neuropathic pain, bed side examination
and quantitative sensory testing. This study will further collect data regarding prevalence of NePC, general health status,
mental health status, functioning, pain attribution and quality of life.
Discussion: The rationale for this study is to provide detailed information on the clinimetric quality of the PDQ-Dlv and
DN4-Dlv in Dutch speaking countries. Our innovative multi-factorial approach should help achieve more reliable diagnosis
and quantification of a NePC in patients with chronic pain.
Trial registration: The Netherlands National Trial Register (NTR3030).
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The International Association for the Study of Pain
(IASP, 2011) defines Neuropathic Pain (NeP) as ‘pain
caused by a lesion or disease of the somatosensory ner-
vous system’ (http://www.iasp-pain.org/Education/Content.
aspx?ItemNumber=1698#Neuropathicpain). This definition
will be used in this study because of its diagnostic specificity,
anatomic precision and the usefulness in clinical as well as
research conditions [1]. NeP plays an important role in the
development and prognosis of chronic pain states. A relevant
example is patients with low back pain (LBP) and neck-
shoulder pain (NSP), which are both highly prevalent and
clinically important medical and societal problems: In this
context, the more severe the NeP, the worse the pain course,
the prognosis and the results of treatment [2-5].
The incidence of NeP in the Dutch general population
is 0.81% or 130.000 new patients in the Netherlands
per year. NeP is 63% more common in women than in
men and peaks between 70 and 79 years of age [6]. LBP
as well as NSP are among the top 10 health problems
encountered in general practice. For men and women,
respectively, the prevalence of LBP and/or NSP in the
general practice is in the range of 55 – 86 and 24 - 113
per 1000 patients a year. In general practice, radiating
pain from the low back or neck occurs in men and women
in respectively 4 - 8 and 10 patients per 1000 patients
[7]/(http://www.nationaalkompas.nl/gezondheid-en-ziekte/
ziekten-en-aandoeningen/bewegingsstelsel-en-bindweefsel/
nek-en-rugklachten/omvang/). The prevalence of chronic
pain syndromes due to peripheral nerve damage (PND) is
3,3 per 1000 per year [8].
Strictly speaking, the diagnosis of neuropathic pain is a
patho-anatomical diagnosis presuming knowledge regard-
ing nerve injury which is difficult to obtain in the clinical
situation. Thus in the clinical context it is better to speak of
a neuropathic pain component (NePC), which is a clinical
syndrome based on a typical set of clinical symptoms and
signs. Clinically, a NePC is characterized by spontaneous
pain and abnormal pain sensations [9]. NeP is typically de-
scribed as a spontaneous ongoing burning or shooting pain
with spontaneous sharp exacerbations and somatosensory
abnormalities after a (non-) noxious stimulus [10].
As a rule, a NePC has a considerable impact on the
quality of daily life [6]. Hence it is important for physi-
cians in daily practice (specialist care as well as primay
care) to diagnose the presence and severity of a NePC in
individual patients. In clinical practice it is, however,
often difficult to reliably diagnose a NePC in (sub)acute
and chronic pain of the low back and neck shoulder re-
gion. The diagnosis of a NePC is at present primarily
based on clinical examination by a physician including
sensory examination. Quantitative sensory testing (QST)
may provide extra information for selected clinical cases
and in the research context [11,12].Because a reliable diagnosis of the neuropathic pain
component is often difficult to accomplish in routine
practice [2], it would be helpful to have a screening tool
to detect such a component for clinical triage and epi-
demiological purposes [12,13]. Apart from optimal sensi-
tivity and specificity, such a screening tool should be
easy to use in clinical practice, not only for the first visit
but also during follow up. The availability of such a sim-
ple, validated, Dutch language screening tool should im-
prove diagnosis and quantification of a NePC and hence
lead to better therapy. At present, no specific (validated)
instrument to determine the neuropathic component in
LBP, NSP and PND is available in the Dutch language.
The PainDETECT-Questionnaire (PDQ) [2] and the
Douleur Neuropatique 4 Questions (DN4) [14] were ori-
ginally developed and validated in Germany and France,
respectively. Both are considered to be reliable screening
tools with a high sensitivity, specificity and positive
predictive value. Recently, the DN4 and the PDQ have
been translated into a Dutch language version (Dlv) by
Van Seventer et al [15] and Timmerman et al [16],
respectively.
Validation of the Dutch versions of DN4-Dlv and PDQ-Dlv
will improve the identification of a NePC in Dutch pri-
mary and specialist medical care, also facilitating re-
mote follow up evaluation by telephone, internet or
post for clinical and scientific purposes. We chose an
innovative approach which should lead to a more reli-
able identification and quantification of a NePC in pa-
tients with chronic pain. This study will help define
patient groups at risk for a NePC and will help to under-
stand and assess the variability and burden of a NePC in in-
dividual patients.
The aim of this study is to establish the clinimetric qual-
ity, including 2-weeks test-retest reliability, of the PDQ-Dlv
and the DN4-Dlv for use in primary care and specialist
medical care settings in Dutch speaking countries for pa-
tients with chronic pain due to LBP, NSP or known per-
ipheral nerve damage (PND). Follow-up for monitoring
and prognosis properties of DN4-Dlv and PDQ-Dlv for a
NePC will be done over a period of 3 months. Additional
data will be collected regarding NEPC prevalence, general
health status, mental health status, functioning, pain attri-
bution and health related quality of life in patients with
chronic pain.Methods
The medical and ethical review board Committee on
Research Involving Human Subjects region Arnhem-
Nijmegen, Nijmegen, the Netherlands, has given ap-
proval to conduct this study, Dossier number: 2008/348;
NL 25343.091.08; The Netherlands National Trial Register
NTR3030.
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In this study a cross-sectional, observational, research
design with 3-months follow up will be used to study
the clinimetric quality of the DN4-Dlv and PDQ-Dlv
(Figure 1).
Setting
Multicenter recruitment will be take place in academic
pain centres, non-academic pain centres and non-academic
departments of neurology. Patients will be seen by the two
physicians during normal office hours, or when that is not
possible during a special office hour for this study. Fur-
thermore, patients willing to participate in this study from
general practices will also be included in this study via
a special office hour in the clinical trainings centre
of Radboud university medical center (Radboudumc).Specialized pain centers
Departments of neurology
N=438 ,  146 patients in each  patient group
Medical history: Date of birth; gender; dur
mellitus; co-morbidity
Examination by both physicians
Questionnaires:
PDQ
DN4
DRI 
HADS
SF-36
PAS
Patient population:
A. Patients with chronic Low Back Pain
B. Patients with chronic Neck/Shoulder Pain
C. Patients with chronic pain from Peripheral Nerve 
20% QST measurement (n=88)
2 weeks follow-up (PDQ & DN4 + PGIC)
Test-retest reliability
3 months follow-up (PDQ & DN4 + PGIC)
Medical record control for patients with p
the patient still have a probable neuropa
possible, unlikely or definite neuropathic
Prognostic value
Figure 1 Flow-diagram of the study. PDQ: PainDETECT questionnaire; DN
HADS: Hospital anxiety depression scale; RAND-36 : RAND 36-item health s
PGIC: Patients global impression of change.Each patient will be seen by two physicians, independently
of each other, working in the same institute. The medical
background of the participating physicians is diverse (ex-
perienced pain specialists, pain specialist trainees, experi-
enced neurologists and experienced general practitioners).
Participants
The patients will be recruited non-selectively and con-
secutively in the period from September 2009 till July
2013. Inclusion criteria: Male and female adult patients
(>18 years of age) with chronic (>3 months) LBP or NSP
radiating into respectively leg(s) or arm(s) or patients with
chronic pain due to PND. Exclusion criteria: Patients diag-
nosed with malignancy, compression fractures, patients
with painful syndromes of unknown origin or associated
with diffuse pains (such as ankylosing spondylitis orGeneral practices
ation of complaints; presence of diabetes 
Damage
robable neuropathic pain component: Does 
thic pain component or has it become a 
 pain component?
4: Douleur neuropatique 4 questions; DRI : Disability rating index;
urvey; PAS: Pain attribution scale; QST: Quantitative sensory testing;
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substance abuse, inability to fill in the questionnaire ad-
equately, or incapable of understanding Dutch. Subjects
can leave the study at any time for any reason without any
consequences. The investigator can decide to withdraw a
subject from the study for urgent medical reasons. When
an individual subject leaves the study all the information
from the patient will be kept in the database, and possibly
be used for data analysis or withdrawal analysis. Such
patients will be replaced.
Measurements
At the first visit, each patient will be seen by two physi-
cians who will question and examine the patients. They
will then independently classify the patients’ pain as pain
with or without a NePC, based in the IASP NeP criteria
and supported by a standardized assessment form. Next,
the patient will complete seven questionnaires (including
the PDQ and the DN4). Twenty percent of the patients
will additionally undergo QST measurement following
the first visit. Two weeks and three months after the initial
visit three follow-up questionnaires will be sent to the pa-
tient by mail.
Demographics
Date of birth, gender, weight (Kg), length (m), nationality,
nationality of origin, pain medication, smoking (cigarettes
a day), alcohol consumption (units per day) and education
level will be assessed by use of a self completed question-
naire. Pain at this moment will be assessed by use of a
numeric rating scale (0-10, NRS) Medical co-morbidity,
duration of complaints (years/months), presence of dia-
betes mellitus (yes/no), presence of HIV (yes/no), presence
of herpes (yes/no) and undergoing of chemotherapy (yes/no)
are based on interview by the physician and noted by the
physician on the standardized assessment form.
Pain classification
At each centre participating patients will be examined
by two (rater A and B) independent and trained pain
physicians, two experienced neurologists or two experi-
enced general practitioners, working independently of
each other and blinded to the diagnosis of the other
physician. To achieve standardization of the history and
clinical examination all participating physicians will be
trained at the sites. Both physicians will classify the pain
regarding the presence or absence of a NePC based on
history and clinical examination. Level of certainty of
the physicians regarding the pain component classifica-
tion will be assessed by use of a Visual Analogue Scale
(VAS, range 0-100). The findings are noted on the stan-
dardized assessment form by the physician. To monitor
the quality of the clinical examination random quality
checks, by expected/ unexpected visits, will be used.Grading system
The grading system for neuropathic pain as proposed by
Treede et al. [1] will be used as a secondary comparison
with the outcome of both the PDQ-Dlv and DN4-Dlv and
with the outcome of the original pain classification by
the two physicians. This system provides a working hy-
pothesis for the origin of patients’ pain. The criteria are
graded on basis of history and testing in medical exam-
ination [1]: (1) Pain with a distinct neuroanatomically
plausible distribution; (2) A history suggestive of a rele-
vant lesion or disease affecting the peripheral or central
somatosensory system; (3) Demonstration of the distinct
neuroanatomically plausible distribution by at least one
confirmatory test; (4) Demonstration of the relevant le-
sion or disease by at least one confirmatory test lesion or
disease explaining NeP. When the criteria 1-4 are all ful-
filled the pain will be graded as possessing a ‘definite
NePC’. Criteria 1 and 2 and either 3 or 4 will be graded
as ‘probable NePC’. Criteria 1 & 2 without criteria 3 or
4 will be graded as ‘possible NePC’. The pain is ‘unlikely
to have a NePC’ when no criteria, or only criteria 1 or 2,
are graded as present (Table 1). The answers (yes or no)
to the four criteria are noted by the physician on the
standardized assessment form. Three months after the
first consultation by the two physicians the medical rec-
ord of patients with ‘probable NePC’ according to the
grading system will be controlled: i.e. does the patient
still have probable NePC, or does he now have definite
NePC?.
Bedside examination
Bed-side examination of the patient is performed by
both physicians. The aim of this examination is to find
possible abnormalities suggestive for a relevant lesion or
disease which affects the peripheral or central somato-
sensory system [17]. The value of bed-side examination
within the clinical examination is that it will give insight
in the pathology and the localization of the lesion or dis-
ease which is causing the pain. Touch, pin prick, pres-
sure, cold, heath, vibration and temporal summation
were included in the examination to provide proof of a
NePC [10,12,18]. This evaluation will be assessed in a
standardized way. The location indicated by the patient
as the one with maximum pain will be compared with
the mirrored location on the contra lateral side. If the
pain has a double sided character a location without
pain as close as possible to the original mirror site will
be tested for comparison. The outcome is noted by the
physician on the standardized assessment form: a) Is
there a sensation b) is the sensation unpleasant or c) is
the sensation painful (all scored as Yes, No or Unclear).
The response of the patient will be noted on the assess-
ment form. The following tests will be performed in all
patients: Mechanical static allodynia by blunt pressure
Table 1 Outcome of the grading system [1]
Criteria 1: Criteria 2: Criteria 3: Criteria 4: Outcome of the
grading systemPain with a distinct
neuro-anatomically
plausible distribution
History suggestive of a
relevant lesion or disease
affecting the peripheral
or central somatosensory
system
Demonstration of the
distinct neuroanatomically
plausible distribution by at
least one confirmatory test
Demonstration of the relevant
lesion or disease by at least one
confirmatory test lesion or
disease explaining NeP
- - - - Unlikely to be NeP
V - - - Unlikely to be NeP
- V - - Unlikely to be NeP
V V - - Possible NeP
V V V - Probable NeP
V V - V Probable NeP
V V V V Definite NeP
NeP: Neuropathic Pain; V: present; -: absent.
Timmerman et al. BMC Neurology 2014, 14:94 Page 5 of 9
http://www.biomedcentral.com/1471-2377/14/94with a finger at a force which normally doesn’t evoke
pain; Dynamic mechanical allodynia by stroking the skin
with a Soft Brush (SENSElabTM, Brush-05, Somedic AB,
Hörby, Sweden), one movement of 1-2 centimeter and
three movements of 1-2 centimeters (wind-up response);
Mechanical pinprick allodynia by touch of the skin with
a plastic safety pin and a Von Frey hair (TOUCH TESTR,
5.07, 10.0 g, North Coast Medical Inc., Gilroy, USA). Heat
allodynia by using TipThermR (TipTherm, Brüggen,
Germany) in a baby-bottle warmer (ISI mini Baby Bottle
Warmer, Assen, the Netherlands) set at 45 degrees Cel-
sius; Cold allodynia with an ice cube placed on the skin
for 2 seconds and Vibration with a Tuning fork (128 Hz;
Medipharchem, Wormerveer, the Netherlands) applied to
joint, bone or soft tissue in the region of the pain.
Quantitative sensory testing
Over the last two decades, QST has been developed to
complement traditional neurological bedside examination
in the analysis of somatosensory aberrations [19,20]. In
theory, greater precision in assessing the functionality of
the somatosensory systems is the main advantage of QST
over standard bedside examination. QST improves diag-
nostic procedures and can be helpful for treatment moni-
toring [11,21]. The protocol we chose is the Nijmegen
Aalborg Screening QST Paradigm (NASQ Paradigm) [22].
This maps pain sensitivity at multiple sites by measuring
the responses (i.e. painful sensations) evoked by mechan-
ical and electrical non invasive stimuli and measures the
patient’s capacity to modulate pain using the Conditioned
Pain Modulation [23], previously termed Diffuse Noxious
Inhibitory controls (DNIC) or Heterotopic Noxious Con-
ditioning Stimulation (HNCS) [24]. In this study the QST
is used to quantify alterations in sensory processing due to
the NePC (sensory profiling) in a sub-sample of patients
with LBP, NSP and PND (20% of the total population
under study, n = 88, equally but randomly divided over all
three pain syndromes). Instructions are standardized andwill be read to the patient from an instruction sheet. Pres-
sure Pain Thresholds (PPT) will be tested by use of an
pressure algometer (Somedic sales AB, Hörby, Sweden).
PPT will be measured on the left and right bodyside
once at each location: Thenar (middle part), musculus
trapezius pars median (middle part), musculus rectus
femoral (15 cm above patella) and m. abductor hallucis
(middle part). Electrical pain thresholds (EPT) will be
tested by use of the QST-3 device (JNI Biomedical ApS,
Klarup, Denmark) on the left and right body side. Meas-
urement locations are the musculus trapezius pars me-
dian (middle part) and the musculus rectus femoris
(20 cm above patella). Electrical pain thresholds (EPT)
are assessed and expressed in milli-Ampère. Single
pulse evoked pain measurement is performed by one
pulse at 150% of the EPT and assessed on a VAS. Sum-
mation (i.e. Electric Wind-Up response (E-WUR)) is
measured by a train of five pulses at 150% of the EPT
and assessed on as VAS. Conditioned Pain Modulation
(CPM) [23,25] will be assessed. Electrical Pain Toler-
ance Thresholds (EPTT) (test stimulation) are assessed
and expressed in milli-Ampère on the m. Rectus femoris
contralateral to the dominant hand. The noxious stimu-
lus (conditioning stimulation) is to immerse the dom-
inant hand until the wrist in a bucket filled with
water and icecubes (‘Ice water bucket test’) [24] for
‘as long as possible, until the moment that the sensa-
tion becomes unbearable and you want to stop dir-
ectly”. The pain will be recorded every 10 seconds on
a NRS. The duration of the immersion (with a max-
imum of three minutes) will be recorded and the pain at
the end of the immersion will be asked. Afterwards, again
the EPTT and the PPT on the contra lateral m. rectus
femoris are assessed.
Douleur neuropathique 4 questions (DN4)
The DN4 [14,15] (© Pfizer bv. Capelle a/d IJssel, the
Netherlands) consists of 10 items in total, divided in two
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oped to screen components of NeP resulting in a yes/no
answer for the presence of NeP. Questions 1 & 2 are sen-
sory descriptors and have to be filled in by the patient or
assessed by the physician by interview; questions 3 & 4
are based on a sensory examination by the physician.
Question 3 includes two items related to sensory deficits:
‘Is the pain located in an area where the physical examin-
ation may reveal one or more of the following characteris-
tics? Touch hypoesthesia and/or pricking hypoesthesia.
Question 4 includes 1 item related to evoked pain: ‘In
the painful area, can the pain be caused or increased by
brushing? Examination of sensitivity to touch (one move-
ment) will be performed with the use of a soft brush
(SENSElabTM, Brush-05, Somedic AB, Hörby, Sweden).
The soft brush will also be used to evaluate tactile (i.e. dy-
namic mechanical) allodynia (wind-up, with three move-
ments). Examination of sensitivity to touch and pricking
will be performed with the use of a Von Frey hair
(TOUCH TESTR, 5.07, 10.0 g, North Coast Medical Inc.,
Gilroy, USA). Pressure allodynia (i.e. static mechanical
allodynia) is tested by blunt pressure with a finger at a
pressure that does not provoke pain in a normally sensi-
tive area [14]. The findings in the physical tests are noted
by the physician on the standardized assessment form.
The cut-off score for the diagnosis of NeP for the 10-item’
DN4 was determined on 4 times ‘yes’ out of 10 (score
range 0-10). This score gave the highest percentage of
correctly identified patients (86%), sensitivity (82,9%)
and specificity (89,9%). The 7-item’ DN4-interview
(score range 0-7) has a cut-off score of 3 times ’yes’ out of
7 which resulted in a percentage of correctly identified pa-
tients of 79, 5%, 78% sensitivity and 81,2% specificity [14].
PainDetect-Questionnaire (PDQ)
The PDQ (© Pfizer Pharma GmbH 2005, Pfizer bv 2009.
Cappelle a/d IJssel, the Netherlands) was developed in
Germany [2,16]. The PDQ (© Pfizer Pharma GmbH 2005,
Pfizer bv 2009. Cappelle a/d IJssel, the Netherlands) was de-
veloped in Germany [2]. The questionnaire can be filled in
by the patients themselves and was devised to screen for
the presence of a NePC without physical examination. Scor-
ing is performed using a scoring manual and results in a
final screening score for the presence of a NePC: ‘negative’,
a NePC is unlikely (<15%, score range 0-12); ‘unclear’, result
is ambiguous, however a NePC can be present (score range
13-18); or ‘positive’, a NePC is likely (>90%, score range 19-
38). The PDQ was tested as a reliable screening tool with a
percentage of correctly identified patients of 83% for NeP,
sensitivity of 85% and a specificity of 80% [2].
Additional questionnaires
Functioning: Disability Rating Index (DRI) [26]. The self-
administered DRI inquires, in a clinical setting, in 12 itemsabout specified activities (Dressing, Out-door walks,
Climbing stairs, Sitting longer time, Standing bent over
a sink, Carrying a bag, Making a bed, Running, Light work,
Heavy work, Lifting heave objects, Participating in exer-
cise/sports). Score range is from 0 to 100 for each item
on a Visual Analogue Scale (VAS). A higher score indi-
cates more disability. The DRI has a good responsive-
ness (p = 0,0001) and a good test-retest correlation of
0,95. The inter- and Intra-rater reproducibility were re-
spectively 0.99 and 0.98 [26]. Mental health status: The
Hospital Anxiety Depression Scale (HADS) [27] will be
used to assess the presence of anxiety and depressive
states of patients. This self-administered questionnaire
is divided into an anxiety subscale (HADS-A) and a de-
pression subscale (HADS-D), both containing 7-items
with a score range of 0-21. The HADS-Dlv [28] has a
good test-retest reliability for HADS-A, HADS-D and
the total HADS (respectively 0.89; 0.86 and 0.91 p =0.001).
The correlation between the anxiety and the depression
subscale was high (0.43 to 0.73) [28]. Based on the review
by Bjelland [29] a cut-off score for both the HADS-A and
the HADS-D of 8+ gives the best balance in sensitivity
and specificity (approximately 0.80 for sensitivity and spe-
cificity). Pain Attribution: Pain Attribution Scale (PAS)
Additional questions to study the attribution of the pain
in patients. On a 5-point Likert-scale the patient is asked
to rate the influence of several items on the pain com-
plaints. Rating is from ‘totally not of influence on the pain
complaints’ to ‘very much of influence on the pain com-
plaints’. Quality of life: The RAND 36-item Health Survey
(RAND-36) [30] is developed to investigate the health re-
lated quality of life. The short, self-administered question-
naire consists of 8 different scales: Physical functioning,
social functioning, role limitations (physical problem), role
limitations (emotional problem), mental health, pain, gen-
eral health perception and health change. The psychomet-
ric quality of the RAND-36-Dlv was studied by van der Zee
[31,32]. Change (Follow-up, 2 weeks and 3 months): The
Patients Global Impression of Change (PGIC) is a patient
rated instrument which measures changes over time on a
seven-points scale. Score range is from 1 (very much
worse) to 7 (very much improved) [33-35].
Power calculation
In an unselected cohort of chronic LBP patients, 37%
had a high probability of a NePC [2]. Sensitivity and spe-
cificity of the PDQ is respectively 85% and 80% [2] and
the sensitivity and specificity of the DN4 are respectively
83% and 90% [14]. The expected sensitivity and specifi-
city of the Dutch versions of both questionnaires is set
at 80% with an prevalence of 37% and the required lower
95% confidence limit > 0.55. According to Flahault et al
the N cases is 40. From the equation in the first formula by
Flahault, the Ncontrols = 68 [36]. Without prior knowledge
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be determined such that, with high probability (e.g. 95%),
the sample contains sufficient numbers of cases and con-
trols. According to the second formula by Flahault et al:
Ntotal = 132, in each group. Thus in each group 146 pa-
tients will be included (10% drop out). It is expected that
this recruitment will be achievable in the 10 general prac-
tices, 4 pain treatment centres and 2 departments of neur-
ology chosen.Data
All data will be collected from the patients and the phy-
sicians on paper and stored by Radboudumc. Data man-
agement and monitoring will be performed within
MACRO (MACRO, version 4.1.1.3720, Infermed, London,
United Kingdom).Statistical analysis
To establish the clinimetric quality of the PDQ-Dlv and
the DN4-Dlv a comparison will be made between the out-
come of both the screening questionnaires and the ori-
ginal pain classification, the Grading system by Treede
at al. [1], the bedside examination and the QST mea-
surements. The prevalence of a NePC in patients with
LBP and NSP in the Netherlands will be assessed by ex-
trapolating the outcome of this study to the Dutch
population. The monitoring and prognosis of the patient
over a period of three months by use of the PDQ-Dlv and
the DN4-Dlv will be recorded. Data analysis and statistics
will be performed by use of Statistical Package for the
Social Sciences (SPSS version 18.0, SPSS Inc., Chicago,
Illinois, USA). All statistical tests will be two-tailed, for
all statistical analysis the type 1 error will be set on 5%.
Descriptive statistics: The quantitative variables will be
described using mean, standard deviation (SD) and range;
Qualitative variables will be described using frequency
and percentages. To assess central position, dispersion
and distribution of variables, the Kolmogorov-Smirnov
test will be used.
Univariate analysis: Both the physicians assessments
(by rater A and B) will serve as the ‘gold standard’ to as-
sess the presence of a NePC. The internal consistency of
both the physicians assessments and the physical exam-
ination tests of the DN4 will be separately established
for rater A and B by calculating Cronbach’s α that as-
sesses the contribution of each item to the precision of
the measurement by both the physicians assessments
and the examination items of the DN4 questionnaire.
Inter-rater reliability: will be assessed by the agree-
ment of the results obtained by raters A and B for both
the physicians assessments and the examination items of
the DN4. Agreement was determined by calculating
the Cohen’s kappa coefficient.Test-retest reliability: will be assessed for the PDQ and
DN4, after two weeks of completion of the question-
naires during the first visit. Stability of the questionnaire
will be analyzed by measuring the intra-class correlation
coefficient and by use of Cohen’s kappa coefficient of
agreement.
Prognosis and monitoring: will be assessed for the
PDQ and DN4, after three months of completion of
the questionnaires during the first visit. Stability of the
questionnaire will be analyzed by measuring the intra-
class correlation coefficient and by use of Cohen’s kappa
coefficient of agreement.
Correlations: will be calculated between scores and
continuous variables using Pearson correlation coeffi-
cient (i.e. correlation between DN4, PDQ and both the
physicians assessments). A students-t test for independ-
ent groups or a Mann-Whitney’s U test (non-normal
distribution) will be used to compare respectively con-
tinuous or ordinal variables between patients with and
without a neuropatic pain component
Multivariate analysis: Sensitivity and specificity per-
centage of well classified observations and Youden index
(i.e. sensitivity + specificity-1) will be calculated for dif-
ferent values of the score of the questionnaire by logis-
tical regression analysis. Positive and negative predictive
value for both instruments will also be calculated. The
corresponding ROC (receiver operating characteristics)
curves will be plotted and AUC calculated using the
trapezoid method. Discriminant analysis will be used to
analyze complementarily of PDQ and DN4 to each
other.
Discussion
The rationale for this study is to provide detailed infor-
mation on the clinimetric quality, including test-retest
reliability, of the PDQ-Dlv and DN4-Dlv in patients with
LBP, NSP or PND regarding of diagnosing a NePC. A
validation of these questionnaires is necessary for its use
in everyday clinical practice and also in (inter-)national
research to make the outcome comparable in different
countries. The key question of this study is whether a
NePC as assessed by the physician is reflected in the
outcome of the PDQ-Dlv and DN4-Dlv. In already pub-
lished articles both questionnaires have proven to be
useful in daily clinical practice and for research purposes
with good clinimetric qualities [2,14].
This study chose an innovative and wide ranging ap-
proach to diagnose a NePC in patients in based on a
more reliable identification and qualification of a NePC.
In the absence of an internationally accepted ‘gold stand-
ard’ [12] the challenge was to find a method to examine
the patients in a standardized manner to assess a NePC.
The opinion of two physicians about a NePC, the most
frequently used standard, will be used in this study and is
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et al [2] and Bouhassira et al. [14]. Together with the grad-
ing system [1], sensory bed-side examination and QST we
will aim to confirm the diagnosis of a NePC, also follow-
ing the NeuPSIG guidelines for the assessment of neuro-
pathic pain [12]. Screening for nerve damage on basis of
sensory bed side examination will be performed by both
the physicians. The aim of this examination is to find pos-
sible abnormalities suggestive for a relevant lesion or dis-
ease which affects the peripheral or central somatosensory
system [17]. The value of bed-side examination within the
clinical examination is that it will give insight into the
pathology and the localization of the lesion or disease
which is causing the pain. Touch, pin prick, pressure, cold,
heath, vibration and temporal summation were included
in the examination to assess the NePC of pain [10,12,18].
For heat allodynia we use a Tip-ThermR in a baby-bottle
warmer at 45 degrees Celsius. To our knowledge we are
the first to use this method. Because a bottle warmer has a
reasonably good thermostat, the temperature of the water
inside, and thus the TipThermR, will be kept at the set
temperature. In this study we did not use the DFNS sen-
sory testing protocol [19,20] but our own NASQ-protocol.
This because we were interested in using QST to assess the
altered pain processing, including changes in function of en-
dogenous pain modulation, that may underlie chronic pain
conditions, instead of testing small and large nerve-fibre
function and the nerve damage related sensory changes [21].
This study will aim to try to define patient groups at risk
and to understand and assess the variability and burden
of a NePC in individual patients. The PDQ [2] outcome
is an ordinal scale, ranging from zero to thirty-eight (a
neuropathic pain component is unlikely-neuropathic
pain component is likely) and thus the question logically
arises whether the PDQ is suitable for the assessment of
the amount of nerve damage.
By the choice for a non-selective consecutive patient
recruitment in specialized pain clinics, neurology clinics
as well as general practices this study aims to validate
the PDQ-Dlv and DN4-Dlv in a general, unselected choronic
pain population. To date, almost all screening question-
naires are validated in a defined, restricted, population, re-
cruited in specialized pain clinics and pre-selected by
precise medical diagnosis (lumbar radicular pain, diabetic
polyneuropathy, postherpetic neuralgia etc.). Our choice
of a non-selcted population might lead to a lower sensitiv-
ity and specificity of the PDQ-Dlv and DN4-Dlv in this study
than published in the original validation studies [2,14].
However, the choice for a non-consecutive population has
the advantage of providing more information relevant to
ordinary clinical practice, in that it is relevant to the unse-
lected ‘general population’.
In conclusion, this study seeks to identify the association
between patient’ symptoms, the signs as found in thebedside examination and outcome of the QST measure-
ments, the general and mental health status, functioning,
pain attribution and quality of life with regard to the out-
come of the PDQ-Dlv and DN4-Dlv in patients with chronic
pain due to LBP, NSP or PND.
Trial status
This study is ongoing. The expected end date of patient
recruitment in this study is July 1, 2013.
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